Insider Transactions Reported by 17 Insiders of
ARROWHEAD PHARMACEUTICALS, INC.
-
Symbol
-
ARWR on Nasdaq
-
Location
-
Pasadena, CA
Quick Takeaways
- ARWR - ARROWHEAD PHARMACEUTICALS, INC. has 17 insiders with reported activity on this page.
- Net insider value flow over the last year: -$37,503,214.
- Recent transaction rows are available for direct filing-level review.
What Changed
- Buy value: ; sell value: $37,503,214.
- Net share flow: <span class="text-red-600">-721,958</span>.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Filed on Form 4
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
See Original Filing
Insiders trading volume in the past year
Insider trading buckets (0-12 months)
ARROWHEAD PHARMACEUTICALS, INC. executives and other stock owners filed with the SEC include:
| Name |
Relationship |
Holdings Value |
Past Year Net Change |
Change % |
Valuation |
Report Date |
| Christopher Richard Anzalone |
Chief Executive Officer, Director |
$251,799,942 |
-$25,543,901 |
-9.2% |
Filing P/S |
02 Jan 2026 |
| Patrick O'Brien |
Coo |
$36,342,471 |
-$3,123,349 |
-7.9% |
Mixed |
06 Jan 2026 |
| James C. Hamilton |
Chief Medical Officer |
$15,210,334 |
-$4,901,561 |
-24% |
Filing P/S |
05 Mar 2026 |
| Daniel Joseph Apel |
Chief Financial Officer |
$11,697,935 |
|
|
Mixed |
06 Jan 2026 |
| Kenneth Allen Myszkowski |
Chief Financial Officer |
$8,967,476 |
|
|
Filing P/S |
04 Jan 2025 |
| Javier San Martin |
Chief Medical Officer |
$7,417,833 |
|
|
Mixed |
04 Jan 2024 |
| Michael S. Perry |
Director |
$4,977,736 |
-$991,738 |
-17% |
Mixed |
16 Dec 2025 |
| Mauro Ferrari |
Director |
$4,833,710 |
-$1,020,513 |
-17% |
Filing P/S |
26 Dec 2025 |
| James Hassard |
Chief Commercial Officer |
$3,951,878 |
|
|
Mixed |
22 Jun 2021 |
| William D. Waddill |
Director |
$3,876,262 |
-$566,038 |
-13% |
Filing P/S |
19 Dec 2025 |
| Tracie Oliver |
Chief Commercial Officer |
$3,213,265 |
|
|
Filing P/S |
02 Jul 2024 |
| Douglas B. Given |
Director |
$2,736,641 |
|
|
Filing P/S |
16 Dec 2024 |
| Victoria Vakiener |
Director |
$2,443,095 |
-$679,491 |
-22% |
Filing P/S |
19 Dec 2025 |
| Adeoye Y. Olukotun |
Director |
$2,300,928 |
-$676,623 |
-23% |
Filing P/S |
19 Dec 2025 |
| Hongbo Lu |
Director |
$2,224,021 |
|
|
Mixed |
16 Dec 2025 |
| Douglas S. Ingram |
Director |
$1,869,396 |
|
|
Mixed |
16 Dec 2025 |
| Marianne de Backer |
Director |
$1,168,448 |
|
|
Mixed |
10 Jan 2023 |
Recent Insider Transactions by Companies or Individuals for ARROWHEAD PHARMACEUTICALS, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider |
Symbol |
Class |
Transaction |
% |
Value $ |
* Price $ |
Shares |
Shares Owned |
Date |
Ownership |
| James C. Hamilton |
ARWR |
Common Stock |
Sale |
-4.05% |
$641,900 |
$64.19 |
-10,000 |
236,958 |
05 Mar 2026 |
Direct |
| James C. Hamilton |
ARWR |
Common Stock |
Award |
43.6% |
|
|
75,000 |
246,958 |
06 Jan 2026 |
Direct |
| Daniel Joseph Apel |
ARWR |
Common Stock |
Award |
74.1% |
|
|
75,000 |
176,200 |
06 Jan 2026 |
Direct |
| Patrick O'Brien |
ARWR |
Common Stock |
Award |
15.9% |
|
|
75,000 |
547,408 |
06 Jan 2026 |
Direct |
| Patrick O'Brien |
ARWR |
Common Stock |
Gift |
-0.53% |
|
|
-2,500 |
472,408 |
06 Jan 2026 |
Direct |
| Patrick O'Brien |
ARWR |
Common Stock |
Sale |
-9.44% |
$3,123,349 |
$63.11 |
-49,493 |
474,908 |
05 Jan 2026 |
Direct |
| James C. Hamilton |
ARWR |
Common Stock |
Sale |
-18.9% |
$2,534,661 |
$63.11 |
-40,164 |
171,958 |
05 Jan 2026 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Sale |
-0.35% |
$871,703 |
$66.10 |
-13,187 |
3,792,739 |
02 Jan 2026 |
Direct |
| Patrick O'Brien |
ARWR |
Common Stock |
Gift |
-0.53% |
|
|
-2,800 |
524,401 |
31 Dec 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Sale |
-1.34% |
$3,575,575 |
$69.13 |
-51,726 |
3,805,926 |
29 Dec 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Options Exercise |
1.36% |
|
|
51,726 |
3,857,652 |
29 Dec 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Stock Option (right to buy Common Stock) |
Options Exercise |
-100% |
|
|
-51,726 |
0 |
29 Dec 2025 |
Direct |
| Mauro Ferrari |
ARWR |
Common Stock |
Sale |
-9.83% |
$527,100 |
$70.00 |
-7,530 |
69,053 |
26 Dec 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Sale |
-0.33% |
$861,340 |
$68.44 |
-12,586 |
3,805,926 |
22 Dec 2025 |
Direct |
| William D. Waddill |
ARWR |
Common Stock |
Sale |
-12.9% |
$566,038 |
$67.65 |
-8,367 |
56,563 |
19 Dec 2025 |
Direct |
| Victoria Vakiener |
ARWR |
Common Stock |
Sale |
-21.9% |
$679,491 |
$67.68 |
-10,040 |
35,723 |
19 Dec 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Sale |
-0.35% |
$909,683 |
$67.66 |
-13,445 |
3,818,512 |
19 Dec 2025 |
Direct |
| Adeoye Y. Olukotun |
ARWR |
Common Stock |
Sale |
-22.9% |
$676,623 |
$67.66 |
-10,000 |
33,600 |
19 Dec 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Sale |
-2.17% |
$5,443,462 |
$64.04 |
-85,000 |
3,831,957 |
17 Dec 2025 |
Direct |
| Mauro Ferrari |
ARWR |
Common Stock |
Award |
11.4% |
|
|
7,819 |
76,583 |
16 Dec 2025 |
Direct |
| Hongbo Lu |
ARWR |
Common Stock |
Award |
16.6% |
|
|
7,819 |
54,982 |
16 Dec 2025 |
Direct |
| Michael S. Perry |
ARWR |
Common Stock |
Award |
6.78% |
|
|
7,819 |
123,059 |
16 Dec 2025 |
Direct |
| Victoria Vakiener |
ARWR |
Common Stock |
Award |
20.6% |
|
|
7,819 |
45,763 |
16 Dec 2025 |
Direct |
| Douglas S. Ingram |
ARWR |
Common Stock |
Award |
20.4% |
|
|
7,819 |
46,215 |
16 Dec 2025 |
Direct |
| Adeoye Y. Olukotun |
ARWR |
Common Stock |
Award |
21.8% |
|
|
7,819 |
43,600 |
16 Dec 2025 |
Direct |
| William D. Waddill |
ARWR |
Common Stock |
Award |
13.7% |
|
|
7,819 |
64,930 |
16 Dec 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Sale |
-1.37% |
$3,398,187 |
$62.58 |
-54,298 |
3,916,957 |
16 Dec 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Sale |
-3.17% |
$8,950,615 |
$68.85 |
-130,000 |
3,971,255 |
15 Dec 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Award |
4.59% |
|
|
180,000 |
4,101,255 |
12 Dec 2025 |
Direct |
| Michael S. Perry |
ARWR |
Common Stock |
Sale |
-12.4% |
$991,738 |
$61.03 |
-16,250 |
115,240 |
05 Dec 2025 |
Direct |
| Mauro Ferrari |
ARWR |
Common Stock |
Sale |
-11.3% |
$493,412 |
$56.39 |
-8,750 |
68,764 |
28 Nov 2025 |
Direct |
| James C. Hamilton |
ARWR |
Common Stock |
Sale |
-8.62% |
$700,000 |
$35.00 |
-20,000 |
212,122 |
01 Oct 2025 |
Direct |
| James C. Hamilton |
ARWR |
Common Stock |
Sale |
-6.07% |
$450,000 |
$30.00 |
-15,000 |
232,122 |
12 Sep 2025 |
Direct |
| James C. Hamilton |
ARWR |
Common Stock |
Sale |
-5.72% |
$375,000 |
$25.00 |
-15,000 |
247,122 |
02 Sep 2025 |
Direct |
| James C. Hamilton |
ARWR |
Common Stock |
Sale |
-3.46% |
$187,780 |
$20.00 |
-9,389 |
262,122 |
15 Aug 2025 |
Direct |
| James C. Hamilton |
ARWR |
Common Stock |
Sale |
-0.22% |
$12,220 |
$20.00 |
-611 |
271,511 |
13 Aug 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Sale |
-1.28% |
$583,692 |
$11.49 |
-50,800 |
3,921,255 |
11 Apr 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Sale |
-1.24% |
$543,500 |
$10.87 |
-50,000 |
3,972,055 |
10 Apr 2025 |
Direct |
| Christopher Richard Anzalone |
ARWR |
Common Stock |
Sale |
-0.99% |
$406,145 |
$10.07 |
-40,322 |
4,022,055 |
09 Apr 2025 |
Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.